Pacira Pharmaceuticals (PCRX) 113.94 $PCRX
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:06PM CST
Pacira Pharmaceuticals Inc. (PCRX) announced that it has resolved its issue with the FDA related to the promotional aspects of its lead product Exparel.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), PCRX: 113.94 (-0.91)
More Leading Stocks Showing Better Action
at Investor's Business Daily - Wed Feb 11, 4:50PM CST
A rising number of leaders are showing improving action as IBD's Big Picture Market Pulse outlook changed for the better Tuesday. More stocks have staged breakouts, while others are still working on bases. Molina Healthcare (MOH) blew past a 54.67...
LCI: 57.78 (-0.91), DATA: 99.90 (+1.40), PCRX: 113.94 (-0.91), FRGI: 61.80 (-0.33), MOH: 59.66 (+0.26)
Stocks Mixed, Mostly Unchanged; Apple Extends Gains
at Investor's Business Daily - Wed Feb 11, 1:58PM CST
Stocks were mixed in late-afternoon trade Wednesday as Greece started talks with eurozone finance ministers about a debt compromise. The Nasdaq eked out a small gain, up 0.2%. The S&P 500 gave up 0.2%, and the Dow Jones industrial average fell 0.3%....
T: 34.66 (+0.05), TSLA: 203.77 (+0.89), FSLR: 48.84 (-0.58), NKE: 92.04 (+0.04), ARMH: 49.92 (-0.49), WMT: 85.81 (-0.08), PCRX: 113.94 (-0.91), AAPL: 127.08 (+0.62)
Stocks Mixed In Quiet Session; Pacira, Zoetis Ramp Higher
at Investor's Business Daily - Wed Feb 11, 12:26PM CST
Stocks were quietly mixed in early afternoon trading Wednesday as Greece started talks with eurozone finance ministers about a debt compromise. The Nasdaq picked up 0.2% while the S&P 500 and the Dow Jones industrial average lost 0.3% each. NYSE and...
ACHC: 63.20 (-0.45), ZTS: 45.46 (-0.33), TSLA: 203.77 (+0.89), FSLR: 48.84 (-0.58), AAPL: 127.08 (+0.62), PCRX: 113.94 (-0.91)
Stocks Stay Mixed; Palo Alto Breaks Out
at Investor's Business Daily - Wed Feb 11, 10:49AM CST
Stocks were mixed near Wednesday's halftime as Greece's meeting with eurozone finance ministers was about to get underway. Helped by Apple (AAPL), the Nasdaq rallied 0.3%. The S&P 500 and the Dow Jones industrial average were off 0.1% and 0.2%,...
VDSI: 27.86 (+2.69), PANW: 135.27 (+2.26), PCRX: 113.94 (-0.91), AAPL: 127.08 (+0.62), PAYC: 32.37 (-0.71)
Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA's Office of Prescription Drug Promotion
Business Wire - Wed Feb 11, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced resolution of matters pertaining to certain promotional aspects of EXPAREL detailed in a recent Warning Letter from the U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP). Pacira announced receipt of the Warning Letter on September 25, 2014 and has since been in constructive discussions with OPDP.
PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
Business Wire - Tue Feb 10, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that financial results for the company's fourth quarter and year ended December 31, 2014, will be released before the market opens on Tuesday, February 24, 2015. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Tuesday, February 24, 2015, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 58501383.
PCRX: 113.94 (-0.91)
Intramuscular Drug Delivery Market & Pipeline Insight Report 2015
M2 - Wed Jan 28, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/hg5jlj/intramuscular) has announced the addition of the "Intramuscular Drug Delivery Market & Pipeline Insight" report to their offering. Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery. With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects. Intramuscular Drug Delivery Market & Pipeline Insight Report Findings: - Intramuscular Drug Delivery Mechanism - Global Intramuscular Drug Delivery Market Outlook - Intramuscular Drug Pipeline by Company, Country, Indication & Phase - Intramuscular Drug Pipeline: 364 Drugs - Marketed Intramuscular Drugs: 186 Drugs - Majority Drugs in Phase-I Trials:108 - Global Intramuscular Drug Delivery Market Future Prospects Key Topics Covered: 1. Introduction to Intramuscular Drug Delivery 2. Overview of Different Drug Delivery Mechanisms 3. Intramuscular Drug Delivery Mechanism 4. Global Intramuscular Drug Delivery Market Outlook 5. Global Intramuscular Drug Delivery Market Dynamics 6. Intramuscular Drug Delivery Market Future Prospects 7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase 8. Marketed Intramuscular Drugs by Company, Country & Indication 9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline 10. Competitive Landscape - Antares Pharma - Eli Lily - Glaxo SmithKline - HMD pharmaceuticals - Inovio Pharmaceuticals - Merck - Novartis - Pacira Pharmaceuticals - Pfizer - Pharmajet - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/hg...ramuscular
INO: 6.80 (-0.15), MRK: 58.81 (-0.07), PCRX: 113.94 (-0.91), ATRS: 2.45 (+0.05), NVS: 102.20 (-0.17)
Update: Pacira's Q4 Revenue Expectations
ONeil Trader - at Seeking Alpha - Sat Jan 10, 7:57AM CST
PCRX: 113.94 (-0.91)
Pacira Q4 & 2014 Revenues to Come In Line with Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 3:20PM CST
Pacira Pharmaceuticals, Inc. (PCRX) provided its revenue estimates for fourth-quarter and full-year 2014, both of which were in line with the Zacks Consensus Estimate.
SHPG: 239.82 (+6.11), APRI: 1.84 (-0.08), PCRX: 113.94 (-0.91), BIOD: 1.38 (-0.14)
Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
Business Wire - Thu Jan 08, 3:30PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan. 22, 2015, from approximately 4:00 to 6:30 p.m. ET in New York. Members of the Pacira management team, along with clinical experts, will provide an overview of the Company's future expansion plans for additional EXPAREL(R) indications, as well as the leading DepoFoam(R)-based product candidates.
PCRX: 113.94 (-0.91)
Pacira Pharma reports estimated revenues
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 9:21AM CST
PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
Business Wire - Thu Jan 08, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL(R) and total revenue estimates for the fourth quarter and full-year 2014.
PCRX: 113.94 (-0.91)
3 Incredible Growth Stocks to Watch in 2015 - Analyst Blog
Sweta Killa - Zacks Investment Research - Tue Jan 06, 8:45AM CST
As the U.S. bull market is likely to celebrate its sixth anniversary in early March, growth investing is fast gaining popularity.
ACW: 5.13 (+0.04), PCRX: 113.94 (-0.91), ZNH: 23.42 (-0.57)
Aratana Therapeutics Initiates Pivotal Study for AT-003
PR Newswire - Tue Dec 16, 3:28PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the initiation of the pivotal field effectiveness study for AT-003, the company's innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). AT-003 is an extended release injectable formulation of bupivacaine.
PETX: 16.52 (-0.10), PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals announces change & update to EXPAREL label application
M2 - Mon Dec 15, 5:40AM CST
Pharmaceutical company Pacira Pharmaceuticals (NasdaqGS CRX) reported on Friday the receipt of the US Food and Drug Administration's (FDA) approval of changes to the EXPAREL packaging and label.
PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL(R) Label
Business Wire - Fri Dec 12, 7:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration's (FDA) approval of changes to the EXPAREL packaging and label proposed by the Company as part of a routine label supplement application, submitted on November 27, 2013. The approved label changes are limited to revisions pertaining to the product's storage, instructions of use and use in special populations, and do not impact its indication. To review specific changes, please refer to the updated Prescribing Information at http://www.exparel.com/pdf/EXPAREL_Prescribin...mation.pdf.
PCRX: 113.94 (-0.91)
PCRX DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
PR Newswire - Mon Dec 01, 10:17AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(NasdaqGS: PCRX) stock between April 9, 2012 and September 24, 2014.
PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 113.94 (-0.91)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
GlobeNewswire - Mon Nov 24, 2:19PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company" (Nasdaq CRX) stock between April 9, 2012 and September 24, 2014.
PCRX: 113.94 (-0.91)
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:06PM CST
Pacira Pharmaceuticals Inc. (PCRX) announced that it has resolved its issue with the FDA related to the promotional aspects of its lead product Exparel.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), PCRX: 113.94 (-0.91)
More Leading Stocks Showing Better Action
at Investor's Business Daily - Wed Feb 11, 4:50PM CST
A rising number of leaders are showing improving action as IBD's Big Picture Market Pulse outlook changed for the better Tuesday. More stocks have staged breakouts, while others are still working on bases. Molina Healthcare (MOH) blew past a 54.67...
LCI: 57.78 (-0.91), DATA: 99.90 (+1.40), PCRX: 113.94 (-0.91), FRGI: 61.80 (-0.33), MOH: 59.66 (+0.26)
Stocks Mixed, Mostly Unchanged; Apple Extends Gains
at Investor's Business Daily - Wed Feb 11, 1:58PM CST
Stocks were mixed in late-afternoon trade Wednesday as Greece started talks with eurozone finance ministers about a debt compromise. The Nasdaq eked out a small gain, up 0.2%. The S&P 500 gave up 0.2%, and the Dow Jones industrial average fell 0.3%....
T: 34.66 (+0.05), TSLA: 203.77 (+0.89), FSLR: 48.84 (-0.58), NKE: 92.04 (+0.04), ARMH: 49.92 (-0.49), WMT: 85.81 (-0.08), PCRX: 113.94 (-0.91), AAPL: 127.08 (+0.62)
Stocks Mixed In Quiet Session; Pacira, Zoetis Ramp Higher
at Investor's Business Daily - Wed Feb 11, 12:26PM CST
Stocks were quietly mixed in early afternoon trading Wednesday as Greece started talks with eurozone finance ministers about a debt compromise. The Nasdaq picked up 0.2% while the S&P 500 and the Dow Jones industrial average lost 0.3% each. NYSE and...
ACHC: 63.20 (-0.45), ZTS: 45.46 (-0.33), TSLA: 203.77 (+0.89), FSLR: 48.84 (-0.58), AAPL: 127.08 (+0.62), PCRX: 113.94 (-0.91)
Stocks Stay Mixed; Palo Alto Breaks Out
at Investor's Business Daily - Wed Feb 11, 10:49AM CST
Stocks were mixed near Wednesday's halftime as Greece's meeting with eurozone finance ministers was about to get underway. Helped by Apple (AAPL), the Nasdaq rallied 0.3%. The S&P 500 and the Dow Jones industrial average were off 0.1% and 0.2%,...
VDSI: 27.86 (+2.69), PANW: 135.27 (+2.26), PCRX: 113.94 (-0.91), AAPL: 127.08 (+0.62), PAYC: 32.37 (-0.71)
Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA's Office of Prescription Drug Promotion
Business Wire - Wed Feb 11, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced resolution of matters pertaining to certain promotional aspects of EXPAREL detailed in a recent Warning Letter from the U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP). Pacira announced receipt of the Warning Letter on September 25, 2014 and has since been in constructive discussions with OPDP.
PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
Business Wire - Tue Feb 10, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that financial results for the company's fourth quarter and year ended December 31, 2014, will be released before the market opens on Tuesday, February 24, 2015. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Tuesday, February 24, 2015, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 58501383. PCRX: 113.94 (-0.91)
Intramuscular Drug Delivery Market & Pipeline Insight Report 2015
M2 - Wed Jan 28, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/hg5jlj/intramuscular) has announced the addition of the "Intramuscular Drug Delivery Market & Pipeline Insight" report to their offering. Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery. With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects. Intramuscular Drug Delivery Market & Pipeline Insight Report Findings: - Intramuscular Drug Delivery Mechanism - Global Intramuscular Drug Delivery Market Outlook - Intramuscular Drug Pipeline by Company, Country, Indication & Phase - Intramuscular Drug Pipeline: 364 Drugs - Marketed Intramuscular Drugs: 186 Drugs - Majority Drugs in Phase-I Trials:108 - Global Intramuscular Drug Delivery Market Future Prospects Key Topics Covered: 1. Introduction to Intramuscular Drug Delivery 2. Overview of Different Drug Delivery Mechanisms 3. Intramuscular Drug Delivery Mechanism 4. Global Intramuscular Drug Delivery Market Outlook 5. Global Intramuscular Drug Delivery Market Dynamics 6. Intramuscular Drug Delivery Market Future Prospects 7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase 8. Marketed Intramuscular Drugs by Company, Country & Indication 9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline 10. Competitive Landscape - Antares Pharma - Eli Lily - Glaxo SmithKline - HMD pharmaceuticals - Inovio Pharmaceuticals - Merck - Novartis - Pacira Pharmaceuticals - Pfizer - Pharmajet - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/hg...ramuscular
INO: 6.80 (-0.15), MRK: 58.81 (-0.07), PCRX: 113.94 (-0.91), ATRS: 2.45 (+0.05), NVS: 102.20 (-0.17)
Update: Pacira's Q4 Revenue Expectations
ONeil Trader - at Seeking Alpha - Sat Jan 10, 7:57AM CST
PCRX: 113.94 (-0.91)
Pacira Q4 & 2014 Revenues to Come In Line with Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 3:20PM CST
Pacira Pharmaceuticals, Inc. (PCRX) provided its revenue estimates for fourth-quarter and full-year 2014, both of which were in line with the Zacks Consensus Estimate.
SHPG: 239.82 (+6.11), APRI: 1.84 (-0.08), PCRX: 113.94 (-0.91), BIOD: 1.38 (-0.14)
Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
Business Wire - Thu Jan 08, 3:30PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan. 22, 2015, from approximately 4:00 to 6:30 p.m. ET in New York. Members of the Pacira management team, along with clinical experts, will provide an overview of the Company's future expansion plans for additional EXPAREL(R) indications, as well as the leading DepoFoam(R)-based product candidates.
PCRX: 113.94 (-0.91)
Pacira Pharma reports estimated revenues
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 9:21AM CST
PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
Business Wire - Thu Jan 08, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL(R) and total revenue estimates for the fourth quarter and full-year 2014.
PCRX: 113.94 (-0.91)
3 Incredible Growth Stocks to Watch in 2015 - Analyst Blog
Sweta Killa - Zacks Investment Research - Tue Jan 06, 8:45AM CST
As the U.S. bull market is likely to celebrate its sixth anniversary in early March, growth investing is fast gaining popularity.
ACW: 5.13 (+0.04), PCRX: 113.94 (-0.91), ZNH: 23.42 (-0.57)
Aratana Therapeutics Initiates Pivotal Study for AT-003
PR Newswire - Tue Dec 16, 3:28PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the initiation of the pivotal field effectiveness study for AT-003, the company's innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). AT-003 is an extended release injectable formulation of bupivacaine.
PETX: 16.52 (-0.10), PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals announces change & update to EXPAREL label application
M2 - Mon Dec 15, 5:40AM CST
Pharmaceutical company Pacira Pharmaceuticals (NasdaqGS
CRX) reported on Friday the receipt of the US Food and Drug Administration's (FDA) approval of changes to the EXPAREL packaging and label. PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL(R) Label
Business Wire - Fri Dec 12, 7:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration's (FDA) approval of changes to the EXPAREL packaging and label proposed by the Company as part of a routine label supplement application, submitted on November 27, 2013. The approved label changes are limited to revisions pertaining to the product's storage, instructions of use and use in special populations, and do not impact its indication. To review specific changes, please refer to the updated Prescribing Information at http://www.exparel.com/pdf/EXPAREL_Prescribin...mation.pdf.
PCRX: 113.94 (-0.91)
PCRX DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
PR Newswire - Mon Dec 01, 10:17AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(NasdaqGS: PCRX) stock between April 9, 2012 and September 24, 2014. PCRX: 113.94 (-0.91)
Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 5:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 113.94 (-0.91)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
GlobeNewswire - Mon Nov 24, 2:19PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(Nasdaq CRX) stock between April 9, 2012 and September 24, 2014. PCRX: 113.94 (-0.91)
